HTD1801


Associated tags: HTD1801, Health, Therapy, Roy Taylor (scientist), ALT, Cholestasis, Liver disease, American Association for the Study of Liver Diseases, HighTide, Chronic liver disease, PSC, NASH, Patient, Diabetes, Doctor of Philosophy, Berberine, Primary biliary cholangitis, Pharmaceutical industry, Medical imaging, Dietary supplement

HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021

Retrieved on: 
Thursday, October 28, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibrosis, Program, UDCA, Astrophysics Strategic Mission Concept Studies, Orphan drug, Weight loss, Central nervous system disease, 2021 Essex County Council election, AASLD, Primary sclerosing cholangitis, Fatty liver disease, Ursodeoxycholic acid, PBC, US, Association, CNS, NAFLD, Fast Track, T2DM, Patient, Liver injury, Roy Taylor (scientist), ALT, Cholestasis, Liver disease, American Association for the Study of Liver Diseases, HighTide, Chronic liver disease, PSC, American Association, Therapy, NASH, Diabetes, Doctor of Philosophy, Berberine, Primary biliary cholangitis, Pharmaceutical industry, Medical imaging, Dietary supplement, HTD1801, HighTide Therapeutics, HTD1801, HIGHTIDE THERAPEUTICS

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
  • The data will be presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2021, being held virtually November 12-15, 2021.
  • We are excited to present new HTD1801 clinical data in both PSC and NASH, said Liping Liu, PhD, Founder and Chief Executive Officer of HighTide.
  • HTD1801 has received Fast Track designation from the US FDA for both PSC and NASH, as well as Orphan Drug designation for PSC.

HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients

Retrieved on: 
Tuesday, September 21, 2021
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ursodeoxycholic acid, Therapy, HighTide, Prevalence, Weight loss, Type 2 diabetes, Fatty liver disease, Liver disease, Berberine, PSC, Inflammation, T2DM, Liver injury, Biliary reflux, Diabetes, Fast Track, Patient, MD, NAFLD, Nausea, Liver cancer, Glycated hemoglobin, NASH, CEO, Magnetic resonance imaging, Degenerative disease, Nature Communications, Disease, Hepatitis, CTCAE, Liver, Lists of diseases, BID, Safety, Fibrosis, Cirrhosis, Orphan drug, US, Diarrhea, Pharmaceutical industry, Medical imaging, NASH, HTD1801, HighTide Therapeutics, NASH, HTD1801, HIGHTIDE THERAPEUTICS

The totality of the data support our expectation that HTD1801 could benefit a significant number of patients with NASH and diabetes, said Liping Liu, CEO of HighTide.

Key Points: 
  • The totality of the data support our expectation that HTD1801 could benefit a significant number of patients with NASH and diabetes, said Liping Liu, CEO of HighTide.
  • NASH is often a liver manifestation of a systemic metabolic disorder, said Stephen Harrison, MD, medical director of Pinnacle Clinical Research and lead author.
  • This trial in patients with presumed NASH and T2DM demonstrated HTD1801s potential to treat NASH while also addressing the underlying metabolic driver of the disease.
  • The study results show that HTD1801 is relatively well tolerated and merits further development as a treatment for NASH with diabetes.

HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021

Retrieved on: 
Monday, June 21, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Health, Hepatology, Medicine, Autoimmune diseases, Primary sclerosing cholangitis, Clinical endpoint, PSC, Ascending cholangitis, PSC, HighTide Therapeutics, HTD1801, PSC, HIGHTIDE THERAPEUTICS, HTD1801

HighTide Therapeutics Inc. (HighTide), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in primary sclerosing cholangitis (PSC) will be presented at the International Liver Congress 2021, 23-26 June.

Key Points: 
  • HighTide Therapeutics Inc. (HighTide), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in primary sclerosing cholangitis (PSC) will be presented at the International Liver Congress 2021, 23-26 June.
  • I am very pleased by these results, said study principal investigator, Kris Kowdley, M.D., Director at Liver Institute Northwest.
  • A Phase II trial of HTD1801 in PSC and NASH comorbid with T2DM met the primary endpoint and several important secondary endpoints.
  • HTD1801 has received Fast Track designation from the US FDA for both PSC and NASH, as well as Orphan Drug designation for PSC.

HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Medical specialties, Hepatitis, Anatomy, Clinical medicine, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Liver disease, T2DM in China, HighTide Therapeutics, HTD1801, T2DM IN CHINA, HIGHTIDE THERAPEUTICS, HTD1801

This approval will further accelerate global development of HTD1801 and clinical progress in treating T2DM, especially T2DM comorbid with non-alcoholic fatty liver disease (NAFLD) in China.

Key Points: 
  • This approval will further accelerate global development of HTD1801 and clinical progress in treating T2DM, especially T2DM comorbid with non-alcoholic fatty liver disease (NAFLD) in China.
  • In our recent Phase II clinical trial in patients with non-alcoholic steatohepatitis (NASH) comorbid with T2DM in the U.S., HTD1801 demonstrated significant reductions in liver fat, liver enzymes, blood glucose, serum lipids and body weight.
  • The approval granted by CDE further accelerates our global development of HTD1801.
  • China has the largest T2DM patient population in the world, and the number of patients is projected to continue increasing rapidly.

HighTide to Present at the BofA Securities 2021 Health Care Conference

Retrieved on: 
Wednesday, April 28, 2021
Health, Diabetes, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Hepatology, Autoimmune diseases, Alcohol and health, Hepatitis, Orphan drugs, Primary sclerosing cholangitis, Liver disease, Gastrointestinal disease, Primary biliary cholangitis, Ursodeoxycholic acid, HighTide Therapeutics, HTD1801, HIGHTIDE THERAPEUTICS, HTD1801

b'HighTide Therapeutics (\xe2\x80\x9cHighTide\xe2\x80\x9d), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, today announced that Company\xe2\x80\x99s Management will provide a corporate presentation and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference to be held May 10-13, 2021.\nHighTide will present at 8:00am EDT on Thursday, May 13, 2021.\nHighTide Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, with a focus on areas of high unmet medical need and lack of effective treatment options.\nHighTide\xe2\x80\x99s lead product candidate, HTD1801, an ionic salt of berberine and ursodeoxycholic acid, is a first-in-class drug and new molecular entity being developed for the treatment of primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC).

Key Points: 
  • b'HighTide Therapeutics (\xe2\x80\x9cHighTide\xe2\x80\x9d), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, today announced that Company\xe2\x80\x99s Management will provide a corporate presentation and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference to be held May 10-13, 2021.\nHighTide will present at 8:00am EDT on Thursday, May 13, 2021.\nHighTide Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, with a focus on areas of high unmet medical need and lack of effective treatment options.\nHighTide\xe2\x80\x99s lead product candidate, HTD1801, an ionic salt of berberine and ursodeoxycholic acid, is a first-in-class drug and new molecular entity being developed for the treatment of primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC).
  • HTD1801 has received Fast Track designation from the U.S. FDA for both PSC and NASH, as well as Orphan Drug designation for PSC.
  • For additional information, please visit https://hightidetx.com/ .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428005045/en/\n'